Abstract |
Pancreatic ductal adenocarcinoma (PDAC) is the worst prognoses among all the malignancies. Now, gemcitabine (Gem) is the first line chemotherapeutic drug for advanced pancreatic cancer. However, Gem is usually ineffective to the PDAC because of high degree of drug resistance. Hypoxia and immune suppressive milieu are the best-described hallmarks of PDAC; therefore, we investigated the impact of hypoxia inducible factor-1 (HIF-1) inhibitor, PX-478, in combination with Gem on the induction of immunogenic cell death (ICD). We verified that combined treatment with Gem/ PX-478 significantly enhanced the anti- tumor effect and increased proportion of tumor infiltrating T-lymphocytes in Panc02-bearing immune-competent but not in immune-deficient mice. Vaccination using Panc02 cell line treated with single agent or in combination showed significant anti- tumor effects. Pancreatic cell lines treated with Gem and PX-478 can induce an increase in eIF2α phosphorylation was correlated with down-regulation of HIF-1α and elicited exposure of CRT and release of HMGB1 and ATP. Only co-treated cells induced DC maturation/phagocytosis and IFN-γ secretion by cytotoxic T lymphocytes. Altogether, combined treatment with Gem/ PX-478 showed significantly inhibition on tumor growth and anti- tumor immunization. We propose that inhibition HIF-1α elicits Gem-induced immune response and eliminates PDAC cells by inducing ICD.
|
Authors | Tiansuo Zhao, He Ren, Li Jia, Jing Chen, Wen Xin, Fan Yan, Jing Li, Xiuchao Wang, Song Gao, Dong Qian, Chongbiao Huang, Jihui Hao |
Journal | Oncotarget
(Oncotarget)
Vol. 6
Issue 4
Pg. 2250-62
(Feb 10 2015)
ISSN: 1949-2553 [Electronic] United States |
PMID | 25544770
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- 2-amino-3-(4'-N,N-bis(2-chloroethyl)amino)phenylpropionic acid N-oxide
- DNA-Binding Proteins
- Elf2 protein, mouse
- HMGB1 Protein
- Hypoxia-Inducible Factor 1, alpha Subunit
- Mustard Compounds
- Phenylpropionates
- Transcription Factors
- Deoxycytidine
- Adenosine Triphosphate
- Gemcitabine
|
Topics |
- Adenosine Triphosphate
(metabolism)
- Animals
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Blotting, Western
- Carcinoma, Pancreatic Ductal
(drug therapy, metabolism, pathology)
- Cell Death
(drug effects, immunology)
- Cell Line, Tumor
- DNA-Binding Proteins
(metabolism)
- Deoxycytidine
(administration & dosage, analogs & derivatives, pharmacology)
- Drug Synergism
- HMGB1 Protein
(metabolism)
- Hypoxia-Inducible Factor 1, alpha Subunit
(antagonists & inhibitors, metabolism)
- Immunization
- Mice, Inbred C57BL
- Mice, Nude
- Microscopy, Fluorescence
- Mustard Compounds
(administration & dosage, pharmacology)
- Pancreatic Neoplasms
(drug therapy, metabolism, pathology)
- Phenylpropionates
(administration & dosage, pharmacology)
- Phosphorylation
(drug effects)
- Survival Analysis
- T-Lymphocytes
(drug effects, immunology, metabolism)
- Transcription Factors
(metabolism)
- Tumor Burden
(drug effects, immunology)
- Gemcitabine
|